2Q EARNINGS: Gilead's Sovaldi beats consensus, just misses higher goal
This article was originally published in Scrip
Executive Summary
Gilead Sciences's $6.4bn in drug sales for the second quarter was 2.4 times the company's product revenue during the same period in 2013, while non-GAAP net income of $3.9bn was 4.7 times Gilead's year-ago income, but investors still may be disappointed by the $3.5bn in Sovaldi (sofosbuvir) sales tallied between April and June.